HIV-1 entry into CD4+ target cells is mediated by cleaved envelope glycoprotein (Env)
trimers that have been challenging to characterize structurally. Here, we describe the crystal …

A vaccine that elicits broadly neutralizing antibodies (bNAbs) against HIV-1 is likely to be
protective, but this has not been achieved. To explore immunization regimens that might …

The HIV-1 fusion peptide, comprising 15 to 20 hydrophobic residues at the N terminus of the
Env-gp41 subunit, is a critical component of the virus-cell entry machinery. Here, we report …

Vaccines are one of the most significant medical interventions in the fight against infectious
diseases. Since their discovery by Edward Jenner in 1796, vaccines have reduced the …

The development of native-like HIV-1 envelope (Env) trimer antigens has enabled the
induction of neutralizing antibody (NAb) responses against neutralization-resistant HIV-1 …

The envelope glycoprotein trimer mediates HIV-1 entry into cells. The trimer is flexible,
fluctuating between closed and more open conformations and sometimes sampling the fully …

Structure determination of the HIV‐1 envelope glycoprotein (Env) presented a number of
challenges, but several high‐resolution structures have now become available. In 2013 …

Abstract Human immunodeficiency virus 1 (HIV-1) infection is initiated by binding of the viral
envelope glycoprotein (Env) to the cell-surface receptor CD4,,–. Although high-resolution …

Antibodies with ontogenies from VH 1-2 or VH 1-46-germline genes dominate the broadly
neutralizing response against the CD4-binding site (CD4bs) on HIV-1. Here, we define with …

Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but
eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here …